Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis2018 · 106 citations
2. 2Exploring disease therapeutic strategies by modulating the TNF-/NF-KB signalling pathway2024
3. 3Advanced Biological Therapies: Principles, Mechanisms and Medical Applications2026
4. 4CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer2024 · 6 citations
5. 5CCAAT/enhancer binding protein β and its role in autoimmune diseases: a promising therapeutic target2026